EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Breast Cancer Research

ISSN 1465-5411 · Springer Science and Business Media LLC

Frequent topics

breast cancer risk12q249p21ATM geneBRCA1 mutation carriersBRCA2 mutation carriersCDKN2A/BDNA damage responsePTHLHZNF365breast cancer susceptibilitycancer susceptibility

Latest articles

  1. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

    Antoniou, Antonis, Karoline B. Kuchenbaecker, Soucy, Penny, Beesley, Jonathan, Chen, Xiaoqing, McGuffog, Lesley, Lee, Andrew, Daniel Barrowdale, Sue Healey, Olga M. Sinilnikova, Caligo, Maria, Loman, Niklas, Katja Harbst, Lindblom, Annika, Arver, Brita, Rosenquist, Richard, Karlsson, Per, Nathanson, Kate, Domchek, Susan, Rebbeck, Tim, Anna Jakubowska, Lubinski, Jan, Katarzyna Jaworska, Durda, Katarzyna, Elżbieta Złowocka-Perłowska, Osorio, Ana, Durán, Mercedes, Andrés, Raquel, Benítez, Javier, Hamann, Ute, Hogervorst, Frans, Theo A.M. van Os, Verhoef, Senno, Hanne E.J. Meijers-Heijboer, Wijnen, Juul, Encarna B. Gómez-García, Ligtenberg, Marjolijn, Kriege, Mieke, Collée, J. Margriet, Margreet G.E.M. Ausems

    Published: 2012-01-01DOI: 10.7916/d8qr4vg8

  2. Rare variants in the ATM gene and risk of breast cancer

    Georgia Chenevix‐Trench, Amanda B. Spurdle, Terry, Mary Beth, Daly, Mary, Saundra M Buys, Melissa C. Southey, Andrulis, Irene, Esther M. John, Kum Kum Khanna, John Llewelyn Hopper, Peter Josef Oefner, Sunil R. Lakhani, Goldgar, David, Healey, Sue, Dowty, James, Leonard Da Silva, Chen, Xiaoqing

    Published: 2011-01-01DOI: 10.7916/d8ws8rks

Volumes

2014 · 22012 · 42011 · 22007 · 42004 · 12003 · 42001 · 102000 · 3

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.